|Aerie Pharmaceuticals, Inc.|
135 US Highway 206
United States - Map
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Its lead product candidate is triple-action Rhopressa, a once-daily eye drop, which completed a Phase IIb clinical trials to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension. The company also develops a product candidate, quadruple-action Roclatan, a single drop fixed-dose combination of Rhopressa and latanoprost, prescribed drug for the treatment of patients with glaucoma. Its preclinical product candidate is AR-13533, a second-generation ROCK/NET inhibitor. The company was founded in 2005 and is headquartered in Bedminster, New Jersey.
|Dr. Vicente Anido Jr., Ph.D.,
Chairman and Chief Exec. Officer
|Mr. Thomas A. Mitro ,
Pres and Chief Operating Officer
|Dr. Thomas J. Van Haarlem M.D.,
Co-Founder and Consultant
|Mr. Richard J. Rubino CPA,
Chief Financial Officer, Principal Accounting Officer and Sec.
|Dr. Casey C. Kopczynski Ph.D. ,
Co-Founder and Chief Scientific Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|